Literature DB >> 32923130

Regulatory T cells do not suppress rather activate human basophils by IL-3 and STAT5-dependent mechanisms.

Mrinmoy Das1, Emmanuel Stephen-Victor1, Jagadeesh Bayry2.   

Abstract

Basophils play an important role in orienting Th2 immune response, and in the pathogenesis of allergic and inflammatory disorders. However, the mechanism by which basophils are kept in check remains unclear and hence we explored the role of regulatory T cells (Treg cells) in this process. We demonstrate that human Treg cells do not suppress rather induce activation of basophils, and promote Th2 responses by IL-3 and STAT5-dependent mechanism.
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

Entities:  

Keywords:  Basophil; CD4+CD25+FoxP3+ regulatory T cell; cancer; immune evasion; Tregs; Th2 response

Mesh:

Substances:

Year:  2020        PMID: 32923130      PMCID: PMC7458635          DOI: 10.1080/2162402X.2020.1773193

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


Basophils are rare granulocytes representing approximately 1% of peripheral blood leukocytes. Basophils are reported to play a role in regulating acquired immunity, particularly by promoting Th2 cell differentiation as well as amplifying humoral memory response.[1] Several studies have also uncovered a role for basophils in protective immunity to pathogens. But dysregulated functions of basophils are associated with many pathologies and in particular allergic and inflammatory diseases. Main reason for the exceptional role of basophils in various pathologies despite their low frequency, is the expression of an array of receptors including FcεRI and cytokine receptors that sense signals derived from diverse sources, and immediate release of inflammatory mediators including cytokines (IL-4, IL-13, IL-6, thymic stromal lymphopoietin and B-cell-activating factor), histamine and leukotriene that support hypersensitive and inflammatory responses.[1] However, the mechanisms by which basophils are kept in check remains unclear and hence recently we explored if CD4+CD25+Foxp3+ regulatory T cells (Treg cells) have the capacity to control the functions of human basophils. Treg cells play a pivotal role in maintaining the peripheral tolerance by inhibiting autoimmune and inflammatory diseases. Treg cells also play a major role in transplantation tolerance and in suppressing tumor immunity.[2] The cellular targets of Treg-mediated suppressor functions include T cells, dendritic cells, B cells, macrophages, monocytes, mast cells, NK cells and NKT cells.[3] Treg cells exert their suppressive functions through several mechanisms that are mediated either by cell-cell contact through inhibitory surface molecules (cytotoxic T lymphocyte antigen-4 (CTLA-4) and lymphocyte-activation gene-3 (LAG-3)), or by secreting regulatory cytokines (TGF-β1 and IL-10) and cytolysis through cytotoxic molecules (granzyme and perforin).[4] As Treg cells suppress the activation of both innate and adaptive immune cells, they are the targets to boost protective immune response to cancer.[2] In order to explore the regulation of human basophils functions by Treg cells, we activated basophils with IL-3 and anti-IgE antibodies that induce basophil activation via IL-3 receptor (IL-3R, a heterodimer composed of IL-3-specific α-subunit and a common β-subunit) and FcεRI-mediated signaling respectively. Interestingly, we found that basophils were refractory to Treg cell-mediated suppression. Despite being under the influence of Treg cells, basophils had undergone activation and anti-IgE-induced degranulation as analyzed by the expression of surface markers (CD203c, CD69, CD63 and CD107a) and histamine in the culture supernatants.[5] We were surprised by the results and hence investigated reasons for the refractoriness of human basophils toward Treg-mediated suppressive effects. As mentioned earlier, Treg cells mediate suppression of target cells by contact-dependent and – independent mechanisms. However, we found that human basophils either in the circulation or residing at secondary lymphoid organs lack CD80 and CD86, the receptors for CTLA-4; and HLA-DR, the receptor for LAG-3.[6] Furthermore, we also found that human basophils do not express TGF-βRII. On the other hand, a subset of human basophils express IL-10Rα, but we found that basophils are not responsive to IL-10.[5] Together, these results could explain underlying reasons for the refractoriness of human basophils toward Treg cell-mediated suppression. Next, we explored if Treg cells could suppress resting basophils. We co-cultured resting basophils with activated memory Treg cells in the absence of any exogenous stimulation or cytokines. Interestingly, we found that Treg cells induced activation of human basophils characterized by the enhanced expression of surface markers associated with basophil activation (CD203c, CD13 and CD69) and secretion of cytokines (IL-8, IL-13 and IL-4). However, Treg-induced basophil activation was not associated with degranulation. Trans-well experiments and blocking studies targeting the intercellular adhesion molecule-1 and inducible T cell costimulator ligand pathway in Treg cells failed to mitigate basophil activation. In contrast, culturing basophils with supernatants from the activated Treg cells recapitulated basophil activation similar to that observed in our co-culture studies.[5] These results suggested that soluble mediators released from the activated Treg cells but not cellular contact drive the activation of basophils. Notably, we found that activated Treg cells secrete IL-3 that could potently activate basophils. To further investigate the role of IL-3 in Treg-induced basophils activation, we perturbed the IL-3-IL-3R pathway by blocking IL-3Rα (CD123) on basophils before culturing with Treg cells. We found that blocking of IL-3Rα abrogated Treg-induced basophil activation. Previous report has shown that IL-3 signaling activates STAT5 in human basophils. To further confirm that IL-3 signaling is important in Treg-induced basophil activation, we pre-treated basophils with STAT5 inhibitor (CAS 285986–31-4) before culturing with activated Treg cells. We found that STAT5 inhibition in basophils abrogated Treg-induced basophils activation.[5] Altogether, these results revealed that IL-3-derived from Treg cells is essential for inducing human basophils activation. What is the importance of our results for tumor immunology? While it has been well established that protective anti-tumor immunity is associated with Th1 responses by activating CD8+ cytotoxic T lymphocytes and NK cell-mediated cytotoxicity, Th2 responses contributes to tumor survival and escape.[7] In this regard, basophils that play a key role in orienting Th2 immune response have been implicated in inhibiting anti-tumor immunity. Recent reports suggest that lymphoid infiltrate in pancreatic ductal adenocarcinomas (PDAC) is comprised mainly of Th2 cells and is predicted to be associated with a poor survival outcome in these patients.[8] Interestingly, basophils were identified as the major contributor of IL-4 in the tumor-draining lymph nodes. The tumor microenvironment is a complex ecosystem where malignant cells are surrounded by diverse nonmalignant cells (immune cells, stromal cells and endothelial cells) that coordinate and orchestrate the immune response to the malignant cells. Notably, tumor cells and innate immune cells secrete several chemokines such as CCL17/22, CCL5, and CXCL9/10 to establish a tolerogenic microenvironment by recruiting Treg cells.[9] In PDAC, chemokines such as CCL7 secreted by alternatively activated monocytes recruit basophils to the tumor draining-lymph nodes. IL-3 secreted by T cells in the tumor microenvironment further activates basophils to orchestrate a Th2 responses by secreting IL-4.[8] Based on our observation it appears that Treg cells might also promote tumor evasion by activating basophils to augment and sustain Th2 responses by secreting IL-3 (Figure 1).
Figure 1.

Tumor cells secrete chemokines that recruit Treg cells to the tumor microenvironment. Our data suggest that tumor-associated Treg cells promote tumor survival and its immune escape by several mechanisms including secretion of IL-3 to activate basophils and to orchestrate Th2 responses.

Tumor cells secrete chemokines that recruit Treg cells to the tumor microenvironment. Our data suggest that tumor-associated Treg cells promote tumor survival and its immune escape by several mechanisms including secretion of IL-3 to activate basophils and to orchestrate Th2 responses. Thus, our data indicate that induction of basophil activation by Treg cells will act as double-edged sword. Promotion of basophil activation by Treg cells in physiology might support various functions of basophils like enhancement of humoral responses and protection against helminthic parasites. However, in case of cancer, it is possible that human basophils might cooperate with tumor-associated Treg cells to promote and sustain Th2 response, thus providing an additional layer of tumor evasion mechanism. Therefore, abrogating basophil functions or mitigating the IL-3/IL-3R axis might promote strong anti-tumor immune response and tumor eradication. In fact, drug-conjugated CD123 (IL-3Rα) monoclonal antibodies are under clinical evaluation for acute lymphoblastic leukemia to target CD123-positive leukemic blast and stem cells.[10] To conclude, human basophils are endowed with a mechanism to escape key checkpoints employed by Treg cells, but are rather licensed to undergo complete activation by IL-3 derived from Treg cells to promote Th2 responses.
  10 in total

Review 1.  Orchestrating the orchestrators: chemokines in control of T cell traffic.

Authors:  Shannon K Bromley; Thorsten R Mempel; Andrew D Luster
Journal:  Nat Immunol       Date:  2008-09       Impact factor: 25.606

2.  Demystification of enigma on antigen-presenting cell features of human basophils: data from secondary lymphoid organs.

Authors:  Emmanuel Stephen-Victor; Mrinmoy Das; Meenu Sharma; Caroline Galeotti; Hélène Fohrer-Ting; Boualem Sendid; Luc Darnige; Benoit Terris; Cécile Badoual; Patrick Bruneval; Srini V Kaveri; Jagadeesh Bayry
Journal:  Haematologica       Date:  2017-02-16       Impact factor: 9.941

3.  Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.

Authors:  Fu Li; May Kung Sutherland; Changpu Yu; Roland B Walter; Lori Westendorf; John Valliere-Douglass; Lucy Pan; Ashley Cronkite; Django Sussman; Kerry Klussman; Michelle Ulrich; Martha E Anderson; Ivan J Stone; Weiping Zeng; Mechthild Jonas; Timothy S Lewis; Maitrayee Goswami; Sa A Wang; Peter D Senter; Che-Leung Law; Eric J Feldman; Dennis R Benjamin
Journal:  Mol Cancer Ther       Date:  2017-11-15       Impact factor: 6.261

4.  Regulatory T cells induce activation rather than suppression of human basophils.

Authors:  Meenu Sharma; Mrinmoy Das; Emmanuel Stephen-Victor; Caroline Galeotti; Anupama Karnam; Mohan S Maddur; Patrick Bruneval; Srini V Kaveri; Jagadeesh Bayry
Journal:  Sci Immunol       Date:  2018-05-25

Review 5.  Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer.

Authors:  James B Wing; Atsushi Tanaka; Shimon Sakaguchi
Journal:  Immunity       Date:  2019-02-19       Impact factor: 31.745

Review 6.  Multifaceted roles of basophils in health and disease.

Authors:  Hajime Karasuyama; Kensuke Miyake; Soichiro Yoshikawa; Yoshinori Yamanishi
Journal:  J Allergy Clin Immunol       Date:  2017-12-14       Impact factor: 10.793

7.  Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer.

Authors:  Lucia De Monte; Michele Reni; Elena Tassi; Daniela Clavenna; Ilenia Papa; Helios Recalde; Marco Braga; Valerio Di Carlo; Claudio Doglioni; Maria Pia Protti
Journal:  J Exp Med       Date:  2011-02-21       Impact factor: 14.307

8.  Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.

Authors:  Helene Pere; Corinne Tanchot; Jagadeesh Bayry; Magali Terme; Julien Taieb; Cecile Badoual; Olivier Adotevi; Nathalie Merillon; Elie Marcheteau; Ve Ronique Quillien; Claire Banissi; Alain Carpentier; Federico Sandoval; Mevyn Nizard; Françoise Quintin-Colonna; Guido Kroemer; Wolf H Fridman; Laurence Zitvogel; Ste Phane Oudard; Eric Tartour
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

Review 9.  Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity.

Authors:  Marco Romano; Giorgia Fanelli; Caraugh Jane Albany; Giulio Giganti; Giovanna Lombardi
Journal:  Front Immunol       Date:  2019-01-31       Impact factor: 7.561

10.  Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients.

Authors:  Lucia De Monte; Sonja Wörmann; Emanuela Brunetto; Silvia Heltai; Gilda Magliacane; Michele Reni; Anna Maria Paganoni; Helios Recalde; Anna Mondino; Massimo Falconi; Francesca Aleotti; Gianpaolo Balzano; Hana Algül; Claudio Doglioni; Maria Pia Protti
Journal:  Cancer Res       Date:  2016-02-12       Impact factor: 12.701

  10 in total
  3 in total

Review 1.  Basophils as a potential therapeutic target in cancer.

Authors:  Jicheng Zhang; Hanlin Yin; Qiangda Chen; Guochao Zhao; Wenhui Lou; Wenchuan Wu; Ning Pu
Journal:  J Zhejiang Univ Sci B       Date:  2021-12-15       Impact factor: 3.066

2.  IFN-γ Induces PD-L1 Expression in Primed Human Basophils.

Authors:  Srinivasa Reddy Bonam; Camille Chauvin; Mano J Mathew; Jagadeesh Bayry
Journal:  Cells       Date:  2022-02-25       Impact factor: 6.600

Review 3.  Is There a Role for Basophils in Cancer?

Authors:  Giancarlo Marone; John T Schroeder; Fabrizio Mattei; Stefania Loffredo; Adriana Rosa Gambardella; Remo Poto; Amato de Paulis; Giovanna Schiavoni; Gilda Varricchi
Journal:  Front Immunol       Date:  2020-09-08       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.